DRUG
MECHANISM · FEATURE
USE
NOTES · ADVERSE
Direct M agonist; not broken down by AChE; no nicotinic action
Postoperative/neurogenic urinary retention, ileus
Activates bowel and bladder smooth muscle
Direct M + N agonist
Glaucoma, intraoperative miosis
Contracts ciliary muscle → opens trabecular meshwork
Direct M agonist, tertiary
Acute angle-closure glaucoma, xerostomia (Sjögren), sweat chloride test stimulus
Potent stimulator of sweat, tears, saliva
Direct M agonist (M3 airway)
Bronchial challenge test
Exaggerated bronchoconstriction = airway hyperreactivity (asthma)
Reversible AChE inhibitor, quaternary (no CNS entry)
Reversal of nondepolarizing blockade, myasthenia, urinary retention, ileus
Give with glycopyrrolate or atropine
Reversible AChE inhibitor, quaternary, longer acting
Myasthenia gravis maintenance
Doesn't treat the autoimmune process (add steroids, thymectomy)
Very short-acting AChE inhibitor
Historic myasthenia test; myasthenic vs cholinergic crisis
Largely replaced by antibody testing
Reversible AChE inhibitor, tertiary (crosses BBB)
Anticholinergic toxicity (atropine, jimsonweed, diphenhydramine)
Avoid in TCA overdose (seizures, asystole)
Donepezil · rivastigmine · galantamine
Centrally acting AChE inhibitors
Alzheimer disease (mild–moderate); rivastigmine also Parkinson dementia
Nausea, diarrhea, bradycardia, vivid dreams
Irreversible (organophosphate) AChE inhibitor
Glaucoma (rare)
Cataracts with long use
Muscarinic: secretions, bradycardia, miosis, bronchospasm · nicotinic: fasciculations, weakness
—
Atropine (muscarinic) ± pralidoxime (organophosphates)
Excess ACh worsens
—
Asthma/COPD, peptic ulcer, bradycardia, bowel or bladder obstruction